Overview

Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Development America, Inc.
Treatments:
Moxifloxacin